Jennifer M Polinski

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis
    Jennifer M Polinski
    Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    Arthritis Rheum 61:745-54. 2009
  2. pmc Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study
    Brian T Bateman
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    BMJ 347:f5416. 2013
  3. pmc Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery
    Brian T Bateman
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    J Thorac Cardiovasc Surg 146:472-8. 2013
  4. pmc Beneficiaries with cardiovascular disease and thePart D coverage gap
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 02120, USA
    Circ Cardiovasc Qual Outcomes 5:387-95. 2012
  5. pmc Association between the Part D coverage gap and adverse health outcomes
    Jennifer M Polinski
    Division of Pharmacoepidemiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    J Am Geriatr Soc 60:1408-17. 2012
  6. pmc Trends in insulin initiation and treatment intensification among patients with type 2 diabetes
    Amanda R Patrick
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA
    J Gen Intern Med 29:320-7. 2014
  7. ncbi request reprint Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, United States Harvard Medical School, Boston, MA, United States Electronic address
    Prim Care Diabetes 8:101-9. 2014
  8. doi request reprint Barriers to insulin progression among patients with type 2 diabetes: a systematic review
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Diabetes Educ 39:53-65. 2013
  9. doi request reprint Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery
    Alexander Kulik
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Circ Cardiovasc Interv 5:590-6. 2012
  10. ncbi request reprint A systematic review of reference pricing: implications for US prescription drug spending
    Joy Li Yueh Lee
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am J Manag Care 18:e429-37. 2012

Detail Information

Publications16

  1. doi request reprint Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis
    Jennifer M Polinski
    Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    Arthritis Rheum 61:745-54. 2009
    ..To date, no one has examined the cost-sharing structures for biologic DMARDs in Part D plans or the resulting cost burden for patients...
  2. pmc Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study
    Brian T Bateman
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    BMJ 347:f5416. 2013
    ..To examine the relation between the type of stress ulcer prophylaxis administered and the risk of postoperative pneumonia in patients undergoing coronary artery bypass grafting...
  3. pmc Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery
    Brian T Bateman
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    J Thorac Cardiovasc Surg 146:472-8. 2013
    ..Intravenous vancomycin exposure has been identified as an independent risk factor for CDI, but this is controversial. It is not known whether vancomycin administered for surgical site infection prophylaxis increases the risk of CDI...
  4. pmc Beneficiaries with cardiovascular disease and thePart D coverage gap
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 02120, USA
    Circ Cardiovasc Qual Outcomes 5:387-95. 2012
    ..The coverage gap remains the subject of Congressional debate; evidence regarding its impact on cardiovascular drug use and health outcomes is needed...
  5. pmc Association between the Part D coverage gap and adverse health outcomes
    Jennifer M Polinski
    Division of Pharmacoepidemiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    J Am Geriatr Soc 60:1408-17. 2012
    ..To determine whether Part D coverage gap entry is associated with risk of death or hospitalization for cardiovascular outcomes...
  6. pmc Trends in insulin initiation and treatment intensification among patients with type 2 diabetes
    Amanda R Patrick
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA
    J Gen Intern Med 29:320-7. 2014
    ....
  7. ncbi request reprint Patterns and trends in insulin intensification among patients with type 2 diabetes: a systematic review
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, United States Harvard Medical School, Boston, MA, United States Electronic address
    Prim Care Diabetes 8:101-9. 2014
    ..The paucity of available studies prevented a comprehensive understanding of patterns and trends in insulin intensification. Such information is needed to assess the quality of pharmacologic care for patients with T2DM. ..
  8. doi request reprint Barriers to insulin progression among patients with type 2 diabetes: a systematic review
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Diabetes Educ 39:53-65. 2013
    ..progression among patients with type 2 diabetes: (1) What are the patient, provider, and health system barriers to insulin progression? (2) Do insulin progression barriers differ between insulin-naive and insulin-experienced patients?..
  9. doi request reprint Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery
    Alexander Kulik
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Circ Cardiovasc Interv 5:590-6. 2012
    ..Controversy exists regarding the optimal preventative therapy for venous thromboembolism (VTE) after coronary artery bypass graft (CABG) surgery. We sought to compare the effectiveness and safety of the most commonly used regimens...
  10. ncbi request reprint A systematic review of reference pricing: implications for US prescription drug spending
    Joy Li Yueh Lee
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    Am J Manag Care 18:e429-37. 2012
    ..These results suggest that reference pricing may be an attractive policy strategy for the US healthcare system...
  11. pmc Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:90-8. 2012
    ....
  12. pmc Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont Street, Suite 3030, Boston, MA, USA
    BMC Endocr Disord 12:20. 2012
    ..abstract:..
  13. pmc Validation of rheumatoid arthritis diagnoses in health care utilization data
    Seo Young Kim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Res Ther 13:R32. 2011
    ..Health care utilization databases have been increasingly used for studies of rheumatoid arthritis (RA). However, the accuracy of RA diagnoses in these data has been inconsistent...
  14. pmc Medicare Part D's effect on the under- and overuse of medications: a systematic review
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, Massachusetts 02120, USA
    J Am Geriatr Soc 59:1922-33. 2011
    ..To evaluate the literature regarding the effect of Medicare Part D on the under- and overuse of specific medications and corresponding health outcomes...
  15. pmc Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 02120, USA
    J Clin Psychopharmacol 32:3-10. 2012
    ..Part D implementation was associated with increased use and affordability of APMs for the elderly without prior drug insurance...
  16. pmc Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs
    Michael A Fischer
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 59:1611-7. 2008
    ..To evaluate state Medicaid prior authorization programs for biologic disease-modifying antirheumatic drugs (DMARDs)...